MLTX Q2 2024 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena

MLTXMoonLake Immunotherapeutics

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$31M

Net Income

-$24M

EPS (Diluted)

$-0.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$545M

Total Liabilities

$15M

Stockholders' Equity

$521M

Cash & Equivalents

$343M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$31M	-$13M	-131.9%
Net Income	-$24M	-$10M	-139.3%

Revenue Segments

License

$300M100%